Not classified by finding typeProfessional / research / regulatoryUnclassified / original material
NIH adult ARV table - single-agent abacavir
Professional / research / regulatory | Existing source category; topic coverage may be incomplete
Product / population: Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal measure: Most ARV label thresholds use Cockcroft-Gault CrCl
Measure label: Measure not yet classified. Read the exact source wording above.
Locally included source-specific summary. Regimen differences are not automatically resolved.
Source dates and additional notes
Source revision: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05
No difference note is recorded here. This does not certify agreement.
Not classified by finding typePreserved GlobalRPh originalsUnclassified / original material
Preserved original GlobalRPh material
Preserved original source | Original source not assigned new topic labels
Product / population: Original source text retained without a new current-label review.
Renal measure: Read the measure stated in the original source.
Measure label: Measure not yet classified. Read the exact source wording above.
Preserved original material; current clinical validation not established.
Source dates and additional notes
Source revision: Not established
Retrieved: 2026-09-05
No difference note is recorded here. This does not certify agreement.
Restriction / avoidance / safetyOfficial-label summariesRestrictions / avoidanceNew v7.4
Trizivir - labeled renal guidance
Official label | Existing source category; topic coverage may be incomplete
Product / population: Abacavir sulfate, lamivudine, and zidovudine (Trizivir), oral tablet
Renal measure: Creatinine clearance (CrCl), mL/min
Measure label: CrCl in mL/min. Read the exact source wording above.
Selected renal passages reviewed; independent clinician adjudication pending.
Source dates and additional notes
Source revision: DailyMed SPL version 2, posted Apr 28, 2014
Retrieved: 2026-11-07
1 documented source differences / product cautions
Restriction / avoidance / safetyRX List label mirrorsRestrictions / avoidanceNew v7.4
Trizivir - selected RX renal passage
RX List label mirror | Existing source category; topic coverage may be incomplete
Product / population: Abacavir sulfate, lamivudine, and zidovudine (Trizivir), oral tablet
Renal measure: Use the renal measure explicitly present in the RX passage.
Measure label: Measure not yet classified. Read the exact source wording above.
Selected renal passages reviewed; independent clinician adjudication pending.
Source dates and additional notes
Source revision: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07
This mirror and the underlying product label share a source family.
1 documented source differences / product cautions
Restriction / avoidance / safetyOfficial-label summariesRestrictions / avoidanceNew v7.4
Triumeq - labeled renal guidance
Official label | Existing source category; topic coverage may be incomplete
Product / population: Abacavir/dolutegravir/lamivudine (Triumeq), fixed-dose oral tablet
Renal measure: Creatinine clearance (CrCl), mL/min
Measure label: CrCl in mL/min. Read the exact source wording above.
Selected renal passages reviewed; independent clinician adjudication pending.
Source dates and additional notes
Source revision: DailyMed SPL version 30, posted Jan 26, 2026
Retrieved: 2026-11-07
1 documented source differences / product cautions
Restriction / avoidance / safetyRX List label mirrorsRestrictions / avoidanceNew v7.4
Triumeq - selected RX renal passage
RX List label mirror | Existing source category; topic coverage may be incomplete
Product / population: Abacavir/dolutegravir/lamivudine (Triumeq), fixed-dose oral tablet
Renal measure: Use the renal measure explicitly present in the RX passage.
Measure label: Measure not yet classified. Read the exact source wording above.
Selected renal passages reviewed; independent clinician adjudication pending.
Source dates and additional notes
Source revision: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07
This mirror and the underlying product label share a source family.
1 documented source differences / product cautions
Dose / interval guidanceProfessional / research / regulatoryRestrictions / avoidanceUnstudied ranges / evidence gaps
NIH adult abacavir/lamivudine - U.S.-focused comparator
Professional / research / regulatory | Manually labeled selected summary
Product / population: Adult U.S.-focused ABC/3TC fixed-combination guidance used to compare an international KIVEXA source; not proof of KIVEXA U.S. approval.
Renal measure: CrCl mL/min; most ARV label recommendations use Cockcroft-Gault.
Measure label: CrCl in mL/min. Read the exact source wording above.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Source dates and additional notes
Source revision: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07
1 documented source differences / product cautions
Restriction / avoidance / safetyRX List label mirrorsRestrictions / avoidanceUnstudied ranges / evidence gaps
GlobalRPh RX List - KIVEXA
RX List label mirror | Manually labeled selected summary
Product / population: International KIVEXA 600/300 mg fixed-dose source; not a newly verified U.S. product label.
Renal measure: CrCl mL/min; source uses <50 threshold.
Measure label: CrCl in mL/min. Read the exact source wording above.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Source dates and additional notes
Source revision: April 2018
Retrieved: 2026-09-07
Australian product-source comparison only; not a claim of U.S. KIVEXA approval.
1 documented source differences / product cautions
Monitoring / qualitative cautionOfficial-label summariesMonitoring / toxicity / cautionsNew v7.4
Tymlos - labeled renal guidance
Official label | Existing source category; topic coverage may be incomplete
Product / population: Abaloparatide (Tymlos), subcutaneous injection
Renal measure: Renal impairment categories as defined by the cited product label
Measure label: Measure not yet classified. Read the exact source wording above.
Selected renal passages reviewed; independent clinician adjudication pending.
Source dates and additional notes
Source revision: DailyMed SPL version 19, posted Aug 17, 2026
Retrieved: 2026-11-07
1 documented source differences / product cautions
Monitoring / qualitative cautionRX List label mirrorsMonitoring / toxicity / cautionsNew v7.4
Tymlos - selected RX renal passage
RX List label mirror | Existing source category; topic coverage may be incomplete
Product / population: Abaloparatide (Tymlos), subcutaneous injection
Renal measure: Use the renal measure explicitly present in the RX passage.
Measure label: Measure not yet classified. Read the exact source wording above.
Selected renal passages reviewed; independent clinician adjudication pending.
Source dates and additional notes
Source revision: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07
This mirror and the underlying product label share a source family.
1 documented source differences / product cautions
Qualified no-adjustment statementOfficial-label summariesMonitoring / toxicity / cautionsQualified no-adjustment statementsUnstudied ranges / evidence gaps
DailyMed / VERZENIO exact product label
Official label | Manually labeled selected summary
Product / population: VERZENIO oral tablets; product-specific breast-cancer indications and companion therapies. This renal summary does not choose an oncology regimen.
Renal measure: Cockcroft-Gault CrCl, mL/min; creatinine transport can complicate interpretation
Measure label: CrCl in mL/min. Read the exact source wording above.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Source dates and additional notes
Source revision: 7/2026
Retrieved: 2026-09-09
Exact DailyMed HTML label identity and selected named sections checked. A page update is not proof that renal instructions changed.
No raw SPL XML, original XML hash or separate Drugs@FDA revision-history review was performed.
1 documented source differences / product cautions
Qualified no-adjustment statementRX List label mirrorsMonitoring / toxicity / cautionsQualified no-adjustment statementsUnstudied ranges / evidence gaps
GlobalRPh RX List - VERZENIO
RX List label mirror | Manually labeled selected summary
Product / population: VERZENIO oral tablets; product-specific breast-cancer indications and companion therapies. This renal summary does not choose an oncology regimen.
Renal measure: Cockcroft-Gault CrCl, mL/min; creatinine transport can complicate interpretation
Measure label: CrCl in mL/min. Read the exact source wording above.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Source dates and additional notes
Source revision: Source revision date not established in selected retrieval.
Retrieved: 2026-09-09
Selected sections only. A hosted mirror is not independent confirmation of the underlying label.
1 documented source differences / product cautions
Pharmacokinetic observation onlyRX List label mirrorsPharmacokinetic observations
GlobalRPh RX List - Zytiga
RX List label mirror | Existing source category; topic coverage may be incomplete
Product / population: ZYTIGA formulation; not interchangeable with YONSA.
Renal measure: ESRD on stable hemodialysis.
Measure label: Measure not yet classified. Read the exact source wording above.
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.
Source dates and additional notes
Source revision: Revision date not established in selected retrieval.
Retrieved: 2026-09-07
No difference note is recorded here. This does not certify agreement.
Not classified by finding typeOfficial-label summariesUnclassified / original material
Abiraterone acetate tablets (Yonsa) - selected U.S. label sections
Official label | Existing source category; topic coverage may be incomplete
Product / population: YONSA oral tablets only. Do not transfer dosing, food instructions or milligram equivalence from another abiraterone formulation.
Renal measure: Qualitative renal-impairment statement
Measure label: Measure not yet classified. Read the exact source wording above.
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Source dates and additional notes
Source revision: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
1 documented source differences / product cautions
Pharmacokinetic observation onlyRX List label mirrorsPharmacokinetic observations
GlobalRPh RX List - Yonsa
RX List label mirror | Existing source category; topic coverage may be incomplete
Product / population: YONSA formulation. The cited dialysis study used another abiraterone product.
Renal measure: ESRD on stable hemodialysis; no new cutoff inferred.
Measure label: Measure not yet classified. Read the exact source wording above.
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.
Source dates and additional notes
Source revision: Revision date not established in selected retrieval.
Retrieved: 2026-09-07
1 documented source differences / product cautions
Not classified by finding typeOfficial-label summariesUnclassified / original material
Abrocitinib tablets (Cibinqo, adults) - selected U.S. label sections
Official label | Existing source category; topic coverage may be incomplete
Product / population: Adult CIBINQO oral tablets. This entry does not supply a pediatric regimen.
Renal measure: MDRD eGFR; Table 1 reports mL/minute. Do not silently substitute Cockcroft-Gault CrCl.
Measure label: Measure not yet classified. Read the exact source wording above.
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Source dates and additional notes
Source revision: 6/2026
Retrieved: 2026-09-05
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
1 documented source differences / product cautions
